Strong Q1 2026 performance with revenue more than doubling year-over-year and positive EBITDA. Growth driven by pharmaceutical and food sectors, new product launches, and expanded customer base. Investments and strategic hires support continued expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.